491871-67-1

Basic information

• Product Name: 4-(4-Fluorobenzylamino)-1,2-phenylenediamine
• Synonyms: N~4~-(4-fluorobenzyl)benzene-1,2,4-triaMine;Retigabine Genotoxic Impurity 1: 4-(4-Fluorobenzylamino)-1,2-phenylenediamine;4-(4-Fluorobenzylamino)-1,2-phenylenediamine;N4-[(4-Fluorophenyl)methyl]-1,2,4-benzenetriamine
• CAS NO: 491871-67-1
• Molecular Formula: C₁₃H₁₄FN₃
• Molecular Weight: 231.27
• Product Categories: Chemical Amines;Amines;Aromatics
• Mol File: 491871-67-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 426.9°C at 760 mmHg
• Flash Point: 212°C
• Appearance: /
• Density: 1.296g/cm³
• Vapor Pressure: 1.7E-07mmHg at 25°C
• Refractive Index: 1.698
• CAS DataBase Reference: 4-(4-Fluorobenzylamino)-1,2-phenylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Fluorobenzylamino)-1,2-phenylenediamine(491871-67-1)
• EPA Substance Registry System: 4-(4-Fluorobenzylamino)-1,2-phenylenediamine(491871-67-1)

Safety Data

• Hazardous Substances Data: 491871-67-1(Hazardous Substances Data)

Usage

Description

4-(4-Fluorobenzylamino)-1,2-phenylenediamine is an organic compound with the molecular formula C13H12FN3. It is a derivative of phenylenediamine, featuring a fluorobenzylamine group attached to the 4-position of the phenyl ring. 4-(4-Fluorobenzylamino)-1,2-phenylenediamine is known for its significant role in the pharmaceutical industry due to its key intermediate status in the synthesis of certain drugs.

Uses

Used in Pharmaceutical Industry:
4-(4-Fluorobenzylamino)-1,2-phenylenediamine is used as a key intermediate in the synthesis of Retigabine (R189050) for its application as an anticonvulsant medication. Retigabine is specifically designed to treat epilepsy by enhancing the activity of neuronal voltage-gated potassium channels, which helps in stabilizing neuronal membranes and reducing the frequency of seizures. 4-(4-Fluorobenzylamino)-1,2-phenylenediamine's role in the synthesis of Retigabine highlights its importance in developing therapeutic solutions for neurological disorders.

InChI:InChI=1/C13H14FN3/c14-10-3-1-9(2-4-10)8-17-11-5-6-12(15)13(16)7-11/h1-7,17H,8,15-16H2

Upstream product

• 1263404-74-5 2-amino-4-(4-fluorobenzylamino)-nitrobenzene 
• 5307-14-2 2-nitro-1,4-phenylenediamine 
• 459-57-4 4-fluorobenzaldehyde 
• 150812-22-9 2-amino-5-(4-fluorobenzylideneamino)nitrobenzene 
• 150812-21-8 1-N-[(4-fluorophenyl)methyl]-3-nitrobenzene-1,4-diamine 
• 5131-58-8 2,4-diaminonitrobenzene 

Downstream Products

• 150812-13-8 retigabine dihydrochloride 
• 1432481-28-1 tert-butyl 2-(tert-butoxycarbonylimino)-4-(N-para-fluorobenzylimino)aniline formate 
• 1263404-73-4 diethyl 4-(4-fluorobenzylamino)-1,2-phenylenedicarbamate 
• 1587701-19-6 C₂₃H₂₈FN₃O₄ 
• 1587701-20-9 diethyl (4-((4-fluorobenzyl)(3-methylbut-2-en-1-yl)amino)-1,2-phenylene)dicarbamate 
• 1587701-12-9 C₂₃H₂₈FN₃O₄ 
• 1432481-07-6 C₂₁H₂₄FN₃O₄ 
• 1587701-27-6 C₂₅H₃₂FN₃O₄ 
• 1587701-28-7 C₂₅H₂₈FN₃O₄ 
• 1587701-29-8 C₂₇H₃₆FN₃O₄ 
• 1432481-08-7 C₂₇H₃₆FN₃O₄ 
• 1587701-23-2 C₂₀H₂₂FN₃O₄ 
• 1587701-24-3 C₂₄H₃₀FN₃O₄ 
• 1587701-25-4 C₂₄H₂₆FN₃O₄ 

Relevant articles and documents

Hydrogen Bond Directed Photocatalytic Hydrodefluorination and Methods of Use Thereof

Methods of synthesizing compounds comprising fluorinated aryl groups are disclosed, wherein said methods utilize hydrogen bond directed photocatalytic hydrodefluorination.

(2-AMINO-4(ARYLAMINO)PHENYL) CARBAMATES

A compound, or pharmaceutically acceptable salt thereof, having a formula (I) wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted alkyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R6 and R7 are each independently H, deuterium, optionally- substituted alkyl, or R6 and R7 together form a carbocyclic; R8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R8 is 4-halophenyl, then R2 is substituted alkyl or branched alkyl or at least one of R6 or R7 is not H; and R30, R31 and R32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.

NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medcine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.